Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.
暂无分享,去创建一个
Eun Ji Kim | Theodoros P. Zanos | J. M. Crawford | T. Zanos | M. Diefenbach | J. Crawford | L. Becker | M. Narasimhan | K. Davidson | M. Qiu | N. Hajizadeh | D. Barnaby | S. Cohen | J. Hirsch | S. Richardson | T. McGinn | J. Chelico | J. Cookingham | K. Coppa | Andrew J. Dominello | J. Duer-Hefele | L. Falzon | J. Gitlin | Tiffany G Harvin | D. Hirschwerk | Z. Kozel | Lyndonna M Marrast | J. Mogavero | Gabrielle A. Osorio | Lyndonna M. Marrast | Safiya Richardson | Kevin Coppa
[1] F. Messerli,et al. Coronavirus Disease 2019 (COVID‐19): Do Angiotensin‐Converting Enzyme Inhibitors/Angiotensin Receptor Blockers Have a Biphasic Effect? , 2020, Journal of the American Heart Association.
[2] Sharukh Lokhandwala,et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. , 2020, JAMA.
[3] J. Xiang,et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.
[4] A. Moran,et al. Trends in Antihypertensive Medication Monotherapy and Combination Use Among US Adults, National Health and Nutrition Examination Survey 2005–2016 , 2020, Hypertension.
[5] S. Lindstrom,et al. First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.
[6] R. Collins,et al. Contrasting male and female trends in tobacco-attributed mortality in China: evidence from successive nationwide prospective cohort studies , 2015, The Lancet.
[7] D. Diz,et al. Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 , 2005, Circulation.
[8] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.
[9] Notice , 1935, Journal of Symbolic Logic.